Literature DB >> 19343738

Predictors of patient reported outcomes and cost of care in younger men with newly diagnosed prostate cancer.

Ravishankar Jayadevappa1, Sumedha Chhatre, Alan J Wein, S Bruce Malkowicz.   

Abstract

BACKGROUND: The proportion of younger men (<65 years) diagnosed with prostate cancer (PCa) has increased significantly. We sought to analyze the association between race/ethnicity, biochemical recurrence risk and outcomes in younger men with PCa.
METHODS: In this prospective cohort study, we recruited 318 younger men with newly diagnosed PCa. Participants completed generic and prostate-specific Health Related Quality of Life (HRQoL), out-of-pocket cost and satisfaction with care surveys at baseline and at 3, 6, 12, and 24 months of follow-up. Health resource utilization and cost data were obtained from the hospital based administrative databases. We compared time to return to baseline (RTB) of HRQoL scores across groups. Survival curves were used to compare mean time to RTB across groups. Linear mixed effects (LMEs) and generalized linear (GLM) models were used to analyze the association of race/ethnicity and biochemical recurrence groups with outcomes.
RESULTS: African Americans reported lower generic and prostate-specific HRQoL scores at diagnosis and required more time to RTB values for generic HRQoL. The results of LME models showed that low risk of biochemical recurrence was associated with better physical function, vitality, mental health, and general health. For prostate-specific HRQoL items, low risk of biochemical recurrence was associated with impaired urinary function and better bowel function and bowel bother. GLM model showed that treatment, hospital type and comorbidity were associated with cost.
CONCLUSIONS: Biochemical recurrence risk and treatment groups, not ethnicity, were associated poorer post-treatment outcomes. This information is important in planning for and communicating with patients about post-treatment care. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19343738     DOI: 10.1002/pros.20955

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

1.  Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study.

Authors:  Caroleen W Quach; Michelle M Langer; Ronald C Chen; David Thissen; Deborah S Usinger; Marc A Emerson; Bryce B Reeve
Journal:  Qual Life Res       Date:  2016-05-30       Impact factor: 4.147

2.  Estimating incremental costs with skew: a cautionary note.

Authors:  Linnea A Polgreen; John M Brooks
Journal:  Appl Health Econ Health Policy       Date:  2012-09-01       Impact factor: 2.561

Review 3.  Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

Authors:  Ronald C Chen; Peter Chang; Richard J Vetter; Himansu Lukka; William A Stokes; Martin G Sanda; Deborah Watkins-Bruner; Bryce B Reeve; Howard M Sandler
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

4.  An assessment of the use of patient reported outcome measurements (PROMs) in cancers of the pelvic abdominal cavity: identifying oncologic benefit and an evidence-practice gap in routine clinical practice.

Authors:  Miss Charlotte L Moss; Ajay Aggarwal; Asad Qureshi; Benjamin Taylor; Teresa Guerrero-Urbano; Mieke Van Hemelrijck
Journal:  Health Qual Life Outcomes       Date:  2021-01-15       Impact factor: 3.186

5.  Out-of-Pocket Costs and Perceived Financial Burden Associated with Prostate Cancer Treatment in a Quebec Remote Area: A Cross-Sectional Study.

Authors:  Abir El-Haouly; Anais Lacasse; Hares El-Rami; Frederic Liandier; Alice Dragomir
Journal:  Curr Oncol       Date:  2020-11-30       Impact factor: 3.677

6.  The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.

Authors:  Shannon M Lynch; Elizabeth Handorf; Kristen A Sorice; Elizabeth Blackman; Lisa Bealin; Veda N Giri; Elias Obeid; Camille Ragin; Mary Daly
Journal:  PLoS One       Date:  2020-08-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.